Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

The effectiveness of adalimumab treatment for non-infectious uveitis.

Hasegawa E, Takeda A, Yawata N, Sonoda KH.

Immunol Med. 2019 Jul 17:1-5. doi: 10.1080/25785826.2019.1642080. [Epub ahead of print]

PMID:
31315546
2.

Challenges in management of epidemic keratoconjunctivitis with emerging recombinant human adenoviruses.

Gonzalez G, Yawata N, Aoki K, Kitaichi N.

J Clin Virol. 2019 Mar;112:1-9. doi: 10.1016/j.jcv.2019.01.004. Epub 2019 Jan 11. Review.

3.

Different Selected Mechanisms Attenuated the Inhibitory Interaction of KIR2DL1 with C2+ HLA-C in Two Indigenous Human Populations in Southern Africa.

Nemat-Gorgani N, Hilton HG, Henn BM, Lin M, Gignoux CR, Myrick JW, Werely CJ, Granka JM, Möller M, Hoal EG, Yawata M, Yawata N, Boelen L, Asquith B, Parham P, Norman PJ.

J Immunol. 2018 Apr 15;200(8):2640-2655. doi: 10.4049/jimmunol.1701780. Epub 2018 Mar 16.

4.

The tear cytokine profile in patients with active Graves' orbitopathy.

Yang M, Chung Y, Lang S, Yawata N, Seah LL, Looi A.

Endocrine. 2018 Feb;59(2):402-409. doi: 10.1007/s12020-017-1467-2. Epub 2017 Nov 16.

PMID:
29147850
5.

NK Cell Alloreactivity against KIR-Ligand-Mismatched HLA-Haploidentical Tissue Derived from HLA Haplotype-Homozygous iPSCs.

Ichise H, Nagano S, Maeda T, Miyazaki M, Miyazaki Y, Kojima H, Yawata N, Yawata M, Tanaka H, Saji H, Masuda K, Kawamoto H.

Stem Cell Reports. 2017 Sep 12;9(3):853-867. doi: 10.1016/j.stemcr.2017.07.020. Epub 2017 Aug 31.

6.

Dynamic change in natural killer cell type in the human ocular mucosa in situ as means of immune evasion by adenovirus infection.

Yawata N, Selva KJ, Liu YC, Tan KP, Lee AW, Siak J, Lan W, Vania M, Arundhati A, Tong L, Li J, Mehta JS, Yawata M.

Mucosal Immunol. 2016 Jan;9(1):159-70. doi: 10.1038/mi.2015.47. Epub 2015 Jun 17.

PMID:
26080707
7.

The combination of type I IFN, TNF-α, and cell surface receptor engagement with dendritic cells enables NK cells to overcome immune evasion by dengue virus.

Lim DS, Yawata N, Selva KJ, Li N, Tsai CY, Yeong LH, Liong KH, Ooi EE, Chong MK, Ng ML, Leo YS, Yawata M, Wong SB.

J Immunol. 2014 Nov 15;193(10):5065-75. doi: 10.4049/jimmunol.1302240. Epub 2014 Oct 15.

8.

Prevalence and viral load of oncogenic human papillomavirus (HPV) in pterygia in multi-ethnic patients in the Malay Peninsula.

Chong PP, Tung CH, Rahman NA, Yajima M, Chin FW, Yeng CL, Go ES, Chan CM, Yawata N, Yamamoto N.

Acta Ophthalmol. 2014 Nov;92(7):e569-79. doi: 10.1111/aos.12427. Epub 2014 Jul 18.

9.

Identification of contamination in the American type culture collection stock of human adenovirus type 8 by whole-genome sequencing.

Yamane S, Lee AW, Hanaoka N, Gonzalez G, Kaneko H, Ishida S, Kitaichi N, Ohno S, Koyanagi KO, Aoki K, Fujimoto T, Yawata N, Watanabe H.

J Virol. 2013 Jan;87(2):1285-6. doi: 10.1128/JVI.02875-12. Epub 2012 Nov 14. No abstract available.

10.

Dimorphic motifs in D0 and D1+D2 domains of killer cell Ig-like receptor 3DL1 combine to form receptors with high, moderate, and no avidity for the complex of a peptide derived from HIV and HLA-A*2402.

Sharma D, Bastard K, Guethlein LA, Norman PJ, Yawata N, Yawata M, Pando M, Thananchai H, Dong T, Rowland-Jones S, Brodsky FM, Parham P.

J Immunol. 2009 Oct 1;183(7):4569-82. doi: 10.4049/jimmunol.0901734. Epub 2009 Sep 14.

11.

MHC class I-specific inhibitory receptors and their ligands structure diverse human NK-cell repertoires toward a balance of missing self-response.

Yawata M, Yawata N, Draghi M, Partheniou F, Little AM, Parham P.

Blood. 2008 Sep 15;112(6):2369-80. doi: 10.1182/blood-2008-03-143727. Epub 2008 Jun 26.

12.

Synergistic polymorphism at two positions distal to the ligand-binding site makes KIR2DL2 a stronger receptor for HLA-C than KIR2DL3.

Moesta AK, Norman PJ, Yawata M, Yawata N, Gleimer M, Parham P.

J Immunol. 2008 Mar 15;180(6):3969-79.

13.

Cutting Edge: Allele-specific and peptide-dependent interactions between KIR3DL1 and HLA-A and HLA-B.

Thananchai H, Gillespie G, Martin MP, Bashirova A, Yawata N, Yawata M, Easterbrook P, McVicar DW, Maenaka K, Parham P, Carrington M, Dong T, Rowland-Jones S.

J Immunol. 2007 Jan 1;178(1):33-7.

14.

Roles for HLA and KIR polymorphisms in natural killer cell repertoire selection and modulation of effector function.

Yawata M, Yawata N, Draghi M, Little AM, Partheniou F, Parham P.

J Exp Med. 2006 Mar 20;203(3):633-45. Epub 2006 Mar 13. Erratum in: J Exp Med. 2006 Apr 17;203(4):1131.

15.

Single-cell analysis of the human NK cell response to missing self and its inhibition by HLA class I.

Draghi M, Yawata N, Gleimer M, Yawata M, Valiante NM, Parham P.

Blood. 2005 Mar 1;105(5):2028-35. Epub 2004 Nov 4.

16.

Variation within the human killer cell immunoglobulin-like receptor (KIR) gene family.

Yawata M, Yawata N, Abi-Rached L, Parham P.

Crit Rev Immunol. 2002;22(5-6):463-82. Review.

PMID:
12803322
17.

Predominance of group A KIR haplotypes in Japanese associated with diverse NK cell repertoires of KIR expression.

Yawata M, Yawata N, McQueen KL, Cheng NW, Guethlein LA, Rajalingam R, Shilling HG, Parham P.

Immunogenetics. 2002 Nov;54(8):543-50. Epub 2002 Oct 24.

PMID:
12439616
18.

High incidence of glucose intolerance in Vogt-Koyanagi-Harada disease.

Yawata N, Nakamura S, Kijima M, Ikai N, Kanai M, Sugita M, Ohno S.

Br J Ophthalmol. 1999 Jan;83(1):39-42.

Supplemental Content

Loading ...
Support Center